Compare Charles River Laboratories Intl. Inc (CRL) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs S&P500 ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while S&P500 ETF trades at $778.54 (market cap $821.54B). The key difference: S&P500 ETF is far larger — about 57.7× Charles River Laboratories Intl. Inc's market cap, and S&P500 ETF is more actively traded (40,070,358 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and S&P500 ETF for 205 Days on average.
| CRL | SPY | |
|---|---|---|
Market Cap | $14.23B | $821.54B |
Volume | 1,176,885 | 40,070,358 |
Sector | Health | — |
52-Week High | $310.77 | $779.14 |
52-Week Low | $149.93 | $631.99 |
Typical Hold Time | 33 Days | 205 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
SPY, tracking the S&P 500, trades at $773.97, down 0.42% on the day amid mixed market signals. Technical indicators show a bullish trend with moving averages supporting upside momentum, while oscillators remain neutral. The ETF's fundamentals are tied to the broad U.S. equity market, with no specific company financials available, and a future dividend of $1.89 scheduled for October 2026. Recent news highlights concerns over valuation and profit growth expectations for 2027.
The outlook for SPY is cautiously optimistic, driven by bullish technical trends and seasonal patterns, but risks include potential earnings growth slowdown and elevated market valuations. Investors may find opportunity in broad market exposure, though vigilance on macroeconomic indicators and corporate profit trends is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
